Savient Pharmaceuticals (WKN 813149)
Seite 1 von 3 Neuester Beitrag: 23.07.13 11:20 | ||||
Eröffnet am: | 12.06.09 15:17 | von: iceman78 | Anzahl Beiträge: | 55 |
Neuester Beitrag: | 23.07.13 11:20 | von: Joschi307 | Leser gesamt: | 9.353 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 > |
Zur Beobachtung sehr interessant, Newsflow ist auch vorhanden!
Hier ist einiges noch möglihc, oder?
Abwarten und Freuen, lg ice
Hier ist einiges noch möglihc, oder?
Abwarten und Freuen, lg ice
Savient jumps 14% after earnings report
BOSTON (MarketWatch) -- Shares of Savient Pharmaceuticals SVNT +15.95% jumped 14% to 66 cents a share on Wednesday after the biotech group posted a narrowed second-quarter loss. The stock has risen 8% over the last 30 days but has plunged 70% since the beginning of the year. Earlier this week, Savient adopted a shareholders rights plan to deter a possible hostile takeover by stakeholder Tang Capital Partners. Earlier this year, Tang had asserted that Savient was insolvent. On Wednesday, Savient stated it ended the second quarter with $142.2 million in cash and short-term securities. Savient's revenues largely come from its recently approved gout drug Krystexxa, which had sales of $4 million for the second quarter.
http://www.marketwatch.com/story/...s-report-2012-08-08?siteid=yhoof2
BOSTON (MarketWatch) -- Shares of Savient Pharmaceuticals SVNT +15.95% jumped 14% to 66 cents a share on Wednesday after the biotech group posted a narrowed second-quarter loss. The stock has risen 8% over the last 30 days but has plunged 70% since the beginning of the year. Earlier this week, Savient adopted a shareholders rights plan to deter a possible hostile takeover by stakeholder Tang Capital Partners. Earlier this year, Tang had asserted that Savient was insolvent. On Wednesday, Savient stated it ended the second quarter with $142.2 million in cash and short-term securities. Savient's revenues largely come from its recently approved gout drug Krystexxa, which had sales of $4 million for the second quarter.
http://www.marketwatch.com/story/...s-report-2012-08-08?siteid=yhoof2
CEO Discusses Q2 2012 Results - Earnings Call Transcript
http://seekingalpha.com/article/...nings-call-transcript?source=yahoo
http://seekingalpha.com/article/...nings-call-transcript?source=yahoo
Aus der heutige Sicht, sieht es doch sehr attraktiv aus. IMO
Bin gespannt.
GLTA ;)
Bristol-Myers Squibb Co. and Novartis AG both looked at acquiring Savient and passed because of concern about price, according to two people with knowledge of the matter, who declined to be identified because the talks are private. The board of directors will continue to “evaluate strategic alternatives,” Savient said in a statement today.
http://www.bloomberg.com/news/2010-10-25/...g-company.html?cmpid=yhoo
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/...tof=15&frt=2
Bin gespannt.
GLTA ;)
Bristol-Myers Squibb Co. and Novartis AG both looked at acquiring Savient and passed because of concern about price, according to two people with knowledge of the matter, who declined to be identified because the talks are private. The board of directors will continue to “evaluate strategic alternatives,” Savient said in a statement today.
http://www.bloomberg.com/news/2010-10-25/...g-company.html?cmpid=yhoo
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/...tof=15&frt=2
BlackRock Inc. hat aufgestockt!!
Amount beneficially owned:
3113521
Percent of class
4.27%
SC 13G/A amended statement of beneficial ownership 09-10-12
http://investor.savient.com/sec.cfm
Amount beneficially owned:
3113521
Percent of class
4.27%
SC 13G/A amended statement of beneficial ownership 09-10-12
http://investor.savient.com/sec.cfm
Sehr netter Seeking Alpha Artikel über die aktuelle Situation.
http://seekingalpha.com/article/...-rising-from-the-dead?source=yahoo
http://seekingalpha.com/article/...-rising-from-the-dead?source=yahoo
Für einen Freitag ein verdammt guter Lauf.
After Hours: 2,54$
Volumen 13.600
http://www.nasdaq.com/symbol/svnt/after-hours
After Hours: 2,54$
Volumen 13.600
http://www.nasdaq.com/symbol/svnt/after-hours
Savient Receives Positive CHMP Opinion for KRYSTEXXA® Approval in the EU
http://finance.yahoo.com/news/...positive-chmp-opinion-145000794.html
http://finance.yahoo.com/news/...positive-chmp-opinion-145000794.html
Fighting Chronic Problems: Savient’s CEO Explains
http://www.pharmalot.com/2012/10/...c-problems-savients-ceo-explains/
Ein Auszug (-das passt ja zur News vom Freitag!-):
...Pharmalot: Any other milestones coming up?
Ferrari: We’re expecting to hear back from the CHMP in Europe over the next couple of weeks on an opinion. That will be a milestone...
Wird wohl der nächste Schritt:
...Pharmalot: And how is the partnership hunt going?
Ferrari: We’re looking for a partner in Europe and the rest of the world. There are a number of companies that have expressed interest and we’re in active discussions. We don’t want to go it alone in Europe. It would have cost us $30 million or more to go forward in Europe at a time when we were battling on a lot of fronts. But right now, we have two years’ worth of cash. And we’re not under any pressure to raise any more. But we think any partnership ex-US will bring us some good revenues, including what we believe will bring upfront payments and royalties. Right now I think we’re in a pretty good spot...
http://www.pharmalot.com/2012/10/...c-problems-savients-ceo-explains/
Ein Auszug (-das passt ja zur News vom Freitag!-):
...Pharmalot: Any other milestones coming up?
Ferrari: We’re expecting to hear back from the CHMP in Europe over the next couple of weeks on an opinion. That will be a milestone...
Wird wohl der nächste Schritt:
...Pharmalot: And how is the partnership hunt going?
Ferrari: We’re looking for a partner in Europe and the rest of the world. There are a number of companies that have expressed interest and we’re in active discussions. We don’t want to go it alone in Europe. It would have cost us $30 million or more to go forward in Europe at a time when we were battling on a lot of fronts. But right now, we have two years’ worth of cash. And we’re not under any pressure to raise any more. But we think any partnership ex-US will bring us some good revenues, including what we believe will bring upfront payments and royalties. Right now I think we’re in a pretty good spot...
Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors
http://finance.yahoo.com/news/...nces-election-genzyme-133000592.html
Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout
http://finance.yahoo.com/news/...ase-receives-european-164200776.html
GLTA
Bleibe dabei
http://finance.yahoo.com/news/...nces-election-genzyme-133000592.html
Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout
http://finance.yahoo.com/news/...ase-receives-european-164200776.html
GLTA
Bleibe dabei